911
Views & Citations10
Likes & Shares
Oral contraceptives (OCs) are widely used by a
significant number of women, often commencing at early adolescence. Whilst most
research has investigated the physiological effects of OCs, some studies have
identified impacts upon nutritional status of certain vitamins and minerals. In
this context, a report published by the World Health Organization (WHO) is
relevant, since women who take OCs-especially in less well-developed countries
might not always have adequate diet. Furthermore, women whose life style is
unhealthy, those with mal-absorption pathologies, or have genetic polymorphisms
that affect vitamin metabolism might also be at risk of the negative impacts on
an individual’s nutrient status. This literature review investigates the
effects that oral contraceptives might have upon nutrient status. It identifies
potential interactions with Vitamins A, B1, B2, B6, B12, C and E and folic acid
as well as magnesium, zinc, selenium, copper, co-enzyme Q10 and beta-carotene
status. It then examines the possible consequences that induced depletion of
folic acid might cause with especial focus on neural tubes defects in UK, where
food supplementation with this vitamin is not yet mandatory. It suggests that
in those using this form of contraception or hormone replacement therapy, it is
valid to consider appropriate nutritional supplements as a complementary first line
strategy in order to prevent possible vitamin and mineral deficiencies.
Keywords: Oral
contraceptive pill, Vitamins, Micronutrients, Minerals, Folate
INTRODUCTION
Oral
contraceptives (OCs) are nowadays some of the most frequently consumed drugs in
many countries in the developed world and are considered some of the most
effective medications currently available [1]. Combination formulations
containing both oestrogens and progestins are the most frequently used. The
most commonly used oestrogens are Ethinyl estradiol (EE) and mestranol, with
the former the more popular. The combination of hormones is designed to prevent
ovulation [2]. Since their introduction, manufacturers have sought to minimize
side effects in order to improve compliance without impairing efficacy [3,4].
In the low-dose formulations currently used today, combinations of a progestin
and EE at a dose of ≤ 35 mcg are commonplace, with doses as low as 20 mcg
capable of to delivering efficacy without the side-effects of bloating and
breast tenderness, usually associated with oestrogenic activity [5,6].
Over
the past 5 decades interest has grown in possible modifications in nutrient
status and/or metabolic processes that might be induced as a result of the
extensive use of OCs and a publication by the World Health Organisation
highlights that these effects are of high clinical relevance [7-11]. However,
the component responsible for these changes remains yet to be identified [12,13].
METHODS
A
search was conducted of electronic databases of literature published through
March 1, 2019. Initially, the search strategy consisted of out using keywords
and Medical Subject Headings (MeSH) “oral contraceptives” and “nutrient
interactions” and “vitamin interactions”. Using references from this primary
search, additional terms included “vitamin A”, “vitamin B1”, “vitamin B2”,
“vitamin B6”, “Vitamin C”, “Vitamin E”, “folic acid”, “vitamin B12, “copper”,
“magnesium”, “selenium”, “zinc”, “co-enzyme Q10”, “beta-carotene” were
subsequently added and searched. Other references or review articles identified
RESULTS
Vitamin A
It is suggested that estrogens elevate retinol binding protein
production, which transports vitamin A in the blood and this may result in
vitamin A being removed from storage sites such as the liver [14-17].
Vitamin B1
Reports have identified that in women taking oral contraceptives,
activity of the thiamine-dependent enzyme-erythrocyte-transketolase is somewhat
reduced, possibly resulting in possible thiamine deficiency, whilst others do
not concur [17-20]. One study in women using 500 mcg dl-norgestrel and 50 mcg
EE examined the additional needs of thiamine, pyridoxine and riboflavin
required to stabilise their status [21]. It found that daily supplementation
with 2 mg riboflavin and 3 mg thiamine mitigated any declines in nutritional
status, whilst pyridoxine at a daily dose of 10 mg was able to correct defects
in tryptophan metabolism.
Vitamin B2
It is thought OCs may impact upon the absorption of riboflavin or
interfere with metabolism to the active coenzyme species [22,23]. In addition,
reduced urinary excretion of vitamin B2 or lowered activity of erythrocyte
glutathione reductase-indicative of riboflavin deficiency-was observed in those
using OCs [16,18]. Vitamin B2 deficiency is commonly associated with low
socioeconomic status and it has been shown that in groups of these women of
child bearing age that this state is aggravated by the use of OCs [16,22].
Deficiencies of riboflavin in women using low-dose formulations have been shown
to be corrected by supplementation of the vitamin [24]. However, others have
reported, no interaction with OCs when dietary riboflavin intake is adequate
[19,20,25]. These observations suggest that in situations where women are
taking OCs and nutrition is limited supplementation should be considered [17].
Given that headache is a commonly experienced side effect of OC’s, reports that
riboflavin supplementation decreases headache intensity, frequency and
duration, as well as intake of medication, suggest that such a strategy might
also prove of benefit [26].
Vitamin B6
Both OCs and estrogen replacement therapy have been reported to
negatively impact upon metabolism of pyridoxine and reduce levels of the
activated co-enzyme forms of the vitamin-pyridoxamine 5’ phosphate (PMP) and
Pyridoxal 5’ phosphate (PLP) [15,27-35] however others have found otherwise
[36,37]. Evidence that OC’s reduce plasma PLP levels comes from a large
observational study which identified this relationship in 75% of women who did
not take supplements [34] and led to speculation that this situation might be
the cause of the heightened risk of venous thromboembolisms observed in those
taking OCs [32]. More recently, reports suggest that even those using more
modern lower-dose OCs may require supplementation to optimise their vitamin B6
status [13]. However, this is debated by other investigators argue that levels
might return to normal vitamin B6 status despite continued therapy [37]. Some
authors also suggest low pyridoxine levels may contribute to side effects such
as depression, lethargy and fatigue [15,27,30]. In situations where plasma PLP
concentrations are suboptimal and in subsequent pregnancy and lactation, at 5
months gestation, at delivery and later in breast milk ,this situation has been
shown to be perpetuated in those who have taken OC for more than 30 months
[38].
Folic acid
Shortly after the introduction of OCs, studies appeared in the literature
to suggest their consumption might negatively impact on user’s folate status
[39-43]. For example, in 1968 Shojania et al. [44] reported in Lancet that in
comparison to a control group, mean serum folate in OC users was lower and that
the numbers of subnormal folate levels was higher too. They also reported that
the rate of decrease in mean serum folate levels increased with longer duration
of use of OCs, but within 3 months of cessation of use, levels of folate
returned to baseline. Likely mechanisms that have been suggested for these
observations include the possibility that OCs might cause folate polyglutamates
to be malabsorbed and/or increase the rate of urinary excretion of folates,
and/or accelerate folate metabolism through an induction of microsomal enzymes
that metabolise folic acid [43]. Further studies have confirmed these reports,
although others have yielded equivocal findings [45-47]. Potential confounders
contributing to these different results might include differences in dietary
intake, duration of use and compliance with OCs, use of tobacco and alcohol,
and the use of dietary supplements [45]. A recent meta-analysis and systematic
review concluded “Because of the reduction in blood folate concentrations
associated with the use of oral contraceptives, it is critical for women of
childbearing age to continue folate supplementation during oral contraceptive
use” [48]. In 2012, in recognition of this, an oral contraceptive fortified
with folate was made available in some markets as a means of lowering the
hazard of neural tube defects (NTDs) in females who might become pregnant
during OC use or shortly after discontinuation [49,50]. Evidence also suggests
that OCs might enhance the rate of progression of cervical dysplasia to
cervical cancer, and folic acid may be able reverse or reduce the rate of
progression of this dysplasia [51,52].
Vitamin B12
A number of studies of women using OCs have identified mean serum vitamin
B12 levels lower than in nonusers [13-15,32,43,53-58]. However this has not
been replicated in others after up to 6 months of use [28,59,60]. It is has
been reported that in women using OCs, that whilst absorption and the urinary
excretion of vitamin B12 were normal, the total binding capacity for the
vitamin in the serum is significantly reduced and that the levels of a
glycoprotein which protects vitamin B12 from stomach acid
degradation-transcobalamin I-was also reduced compared to non-OC users,
suggestive of them being the causative factors for these observations [43,56].
In a later study, OC consumption was found to be associated with reduced
concentrations of vitamin B12 in serum, with time point discrepancies
continuing over 12 weeks [61].
Just as impaired folate status is an independent NTD risk factor,
inadequate maternal cobalamin status is similarly problematic [62]. This is
possibly due to elevated Methylmalonic acid (MMA) levels, frequently observed
in the onset of vitamin B12 deficiency. Indeed, serum MMA levels >90th
percentile at mid-trimester have been reported to have a 13-fold increased risk
for a pregnancy resulting in a NTD [62]. However, not all authors reports
alterations in MMA concentrations in the urine [63] or plasma homocysteine or
MMA concentrations in those using OCs compared to non-users [56,64].
However, a systematic review concluded that OCs do indeed exert a
negative influence on vitamin B12 status [65] supporting the concept that
supplementation might be considered in OC users [66], especially in those with
an unhealthy lifestyle or inadequate diet, and although cessation of OC use
results in normalisation of levels of the vitamin [59], there are those who
suggest clinicians should recommend appropriate dietary supplementation as a
primary approach to counter potential deficiencies of key vitamins and minerals
in OC users [67].
Vitamin C
It is thought estrogen can increase vitamin C metabolism, and it has been
reported that the use of OCs reduces levels of this vitamin in leukocytes and
platelets [27,57,68,69] with alterations in tissue uptake patterns and changes
in the distribution [17]. In one instance it was shown that over periods of six
months to seven years there is no compromise of vitamin C status providing
adequate dietary intake of ascorbic acid is maintained [70]. However, this
might not always be the case in situations where unhealthy lifestyles, poor
diet or mal-absorption pathologies occur [57]. Recently, in women taking
low-dose OCs, it was reported that compared to controls the former group
experienced significantly elevated levels of malondialdehyde levels in the
plasma, which were associated with a reduction in glutathione peroxidase and
reductase ezymes and indicative of increased oxidative stress [71]. However,
supplementation with vitamins C and E significantly reversed these changes
[71]. It is possible that estrogens can both reduce the absorption of vitamin C
and/or accelerate its catabolism and that stores might be mobilised in the tissues
to prevent oxidation of estrogens [17,72,73].
Vitamin E
The administration of contraceptive steroids in preclinical models,
reduced levels of plasma tocopherol levels, significantly and also increased
vitamin E dietary requirements [74]. Later studies found that supplementation
of this vitamin together with folic acid, significantly lessened the OC induced
oxidative stress in women using this form of contraception [75], leading other
authors, following similar observed outcomes, to recommend women taking these
drugs to supplement with vitamin E [76]. Other researchers have found a
significantly higher level of platelet clotting activity in conjunction with a
reduction in vitamin E plasma levels in OC users which was reversed with administration
of the vitamin [77,78].
Magnesium
Estrogens lower serum levels of magnesium as a result of increasing
uptake by bones and soft tissues resulting in an inverse relationship between
the two [79-81]. Estrogen therapy, whether through use of OCs or HRT, reduces
levels of serum and can result in hypomagnesemia, particularly in those with a
low dietary intake of the mineral or as a result of other causes of its loss
[79,81-85]. The depletion of magnesium can subsequently alter the ratio of calcium/magnesium
ratio which in turn can affect blood coagulation [86] which supports the view
that magnesium supplementation might be considered with OCs, since it is
possible that hypomagnesemia might be associated with thromboembolic side
effects associated with estrogens [78,79].
Zinc
50 years ago, lower levels of zinc were identified in the plasma of OC
users in comparison to those not prescribed them [87], an observation to be
confirmed in later studies likely due to changes in absorption, tissue turnover
or excretion [12,88-91]. Because estrogen can induce a reduction in serum
albumin, this may cause a decrease in the concentration of zinc transported in
the blood [88,92]. Although this effect is not conclusively reported, the
majority of studies support the view that even low dose oral contraceptives negatively
affect the nutritional status of this mineral [12,15,68,90,91,93-98]. Moreover,
a recent systematic review concluded “a decrease in the serum concentrations of
zinc, selenium, phosphorus and magnesium have been reported in OC users with
reductions proportional to the duration of contraceptive use”; suggesting
supplementation might be warranted [65].
Selenium
One study of OCs contraceptive pill users, observed that in addition to a
significant reduction in serum zinc levels, there was a similar negative, but
not statistically significant alteration in selenium level [91]. In a
cross-sectional randomized study of women using oral contraceptives, injectable
or hormonal intra-uterine devices, mean serum selenium levels of all these
subjects were significantly lower than controls [82].
Calcium
Several authors have reported use of OCs by women of young adulthood
through to peri-menopause may have a beneficial effect on bone-mineral density
(BMD) [99-102] through reducing short and long term calcium excretion
[103-105]. However, again this has not been reported by all investigators with
some suggesting age at first use [106], physical activity and race [107] might
be major factors affecting this relationship. This view is supported in a study
of cross-sectional design of women aged 20-35 year which identified that
individuals with the highest BMD were short-term OC users that participated in
long-term exercise, whereas long term exercisers and OC users did not
experience the same benefits [108]. In another, two year, intervention study,
OC users were randomized into two groups, one exercising and the other not
exercising and compared with similarly allocated nonusers. Here total BMD was
elevated in those exercising but lower in users OC’s, and OC use in combination
with exercise delivered an effect that was less suppressive on mechanical
strength at the femoral neck and normal accretion of bone mass [109]. Similar
outcomes were observed by Weaver et al. [110]. A subsequent one year
investigation examined the effect that various doses of calcium supplementation
had on BMD in 18 to 30 year old females using OCs when compared to non-OC
users. It reported a calcium intake of 1000-1100 or 1200-1300 mg/d from
products of a dairy origin provided OC users greater protection from total
spine and hip BMD loss than in those consuming <800 mg/d [111].
Copper
A recent meta-analysis demonstrates even the more recently developed OCs
containing, EE doses of 25-30 mcg frequently raise serum copper levels by
approximately 50% to the between 1.5 and 2 mg/L [112].
Co-enzyme Q 10,
vitamin E and β-carotene
A 2010 study compared the effects of three methods of contraceptive (OC,
transdermal patch and vaginal ring) on serum levels of α- and γ-tocopherol,
co-enzyme Q 10 and total antioxidant capacity (TAOC) in premenopausal women
[113]. In all three types of contraceptive users, serum levels of α-tocopherol
and coenzyme Q10 were observed to be significantly reduced compared with
controls. Other authors had also previously described the similar effects of
HRT in decreasing serum levels of α-tocopherol and coenzyme Q 10 [114]. Estrogen
has also been demonstrated to be associated with reduced serum concentrations
of certain antioxidants that are lipid soluble [115,116]. The same group also
reported that users of OCs had significantly lower levels of plasma β-carotene
[116].
DISCUSSION
The above narrative indicates that oral contraceptive may impact upon
nutritional status of users and here the possible implications of these effects
are examined in a contextual setting.
Hormonal
contraceptive use
Combined oral contraceptives (COCs), are among the most common
contraceptive methods used worldwide by about 9% of married women or those in a
relationship aged 15 to 49 years [117]. They are highly effective if used
consistently and correctly, but their failure rate with typical use is much
higher [118]. The most recent UK Office for National Statistics (ONS) survey
identified OCs accounted for 25% of the total female use [119]. A 2013 UK study
investigated adolescents aged 12-18 years and found that around 20% of these
females received prescriptions for OCs, most of which were for a combined oral
contraceptive (COC) [120]. However, a 2010 study found an increasing number of
women-a five-fold increase in 5 years in UK were also using contraceptive
hormone implants and of those, more than half were aged 24 or under [121]. A
further study found OCs to be the most widely used method in five European
countries [122] with an estimated 22 million users with levels of satisfaction
of over 90%. However, nearly 40% of pregnancies in the world are unintended and
worldwide, incorrect and inconsistent use of COCs appears to be one of the most
common causes of unintended pregnancy [123]. For example, a recent Iranian
study showed that 28% of COC users took them incorrectly [124] and more than
one-quarter (27%) of unintended pregnancies occurred while using a COC [125].
Side effects of oral
contraceptives
A meta-analysis of studies from 19 countries identified COC
discontinuation rate is very high, reaching 44% in the first year [126]. The
main reasons for nearly half (47%) of discontinuations are due to side effects
or health concerns.
Two clinical trials have investigated the effects of daily systemic
multivitamin complex and vitamin B6 supplementation on COC side effects
[66,127]. Subsequently another study assessed the effect of multivitamin use
might have on the rate of continuation of use of OCs and their observed side
effects within the first few cycles of use in 332 women [128]. Nausea, mood
changes, weight gain and breast tenderness were also significantly less common
in the multivitamin group in all cycles, and spotting/irregular bleeding and
dizziness were significantly less common in most of the second, third and sixth
cycle follow-up. It concluded multivitamin supplements could significantly reduce
the side effects of COCs in the initial cycles and improve continuation rates.
Self-reported intakes dietary vitamins B6, B12 and folate were used to
examine the relationship between depression in women who used OCs [129]. OC
users were reported to more depress than counterparts not using OCs, with
depression statistically significantly associated with distinct vitamin intake
quartile levels. When intakes exceeded RDAs for vitamin B12, folate and vitamin
B6 by 75%, 13% and 7%, respectively, OC users were found to be less depressed.
Possibly as a result of these issues, adherence in Western countries to
use of OCs is limited, with a 50% rate of discontinuation at 6 months
[130,131], with side effects most commonly cited as the reason for
discontinuation [130,132,133]. Here weight gain is a reported problem and
although some studies have shown that OCs do not have an effect on this issue
[134,135], including a recent review by Cochrane [136], it is often reported as
a side effect [137]. 40% more females who gained weight have reported
discontinuation of OCs compared to those who did not gain weight [131].
Furthermore, an inverse relationship between obesity and micronutrient
deficiencies is thought to induce alterations in metabolism of leptin and
inflammatory responses [67,138-140]. One investigation [141] assessed almost
40,000 premenopausal Korean females and identified an association of OC use
with a 12% increased risk of obesity. Those with intakes of vitamins A, B1, B2,
B3, C, folate, calcium, potassium and phosphorus less than recommended appeared
particularly susceptible to obesity. The authors concluded efforts should be
considered to increase micronutrient intake in females taking OCs.
Oxidative stress and
oral contraceptive use
A recent study analysed the impact of OCs on pro/antioxidant status in
healthy young women [142]. Typical blood markers of oxidative stress, such as
oxidised glutathione oxidized (GSSG), malondialdehyde (MDA),
gamma-glutamyltranspeptidase (GGT) and Cu, Cu/Zn ratio were determined and in
women taking OCs. This study further confirms that OCs use compromises the
pro/antioxidant imbalance. A further publication [143], found OC use did
influence copper, iron and zinc homeostasis, but that supplementation with zinc
beneficially altered copper utilization in OC users and had a positive effect
on oxidative stress.
Lipidemic effects of
oral contraceptive
OCs have been shown to directly affect metabolism of lipids and
carbohydrate [144-146] with impaired glucose tolerance and insulin secretion,
accompanied by elevated levels of total cholesterol and serum triglycerides
[147-149]. However, given the differences in the formulations used in these
studies-both qualitative and quantitative-their findings remain controversial,
as does the potential association between the use of OCs and cardiovascular
disease risks [150,151]. It is recognized that both vitamins C and E confer
enhanced effects on the profiles of lipids and the impact of the use of COCs on
serum lipids in women over 4 weeks has been investigated in one study [152].
Statistically significantly higher increases in the levels of LDL cholesterol
and triglycerides and LDL were reported in COC users than non-users. In the
group using COCs and receiving vitamins C and E, the HDL/LDL ratio increased as
did the HDL level, whilst triglycerides and LDL decreased significantly in
comparison to those women in other group.
The nutritional
landscape in UK
Given the above data relating to the impact of OCs on the nutrient status
of users it is relevant to examine the prevailing nutritional environment
within which are they likely to reside. Specifically, a recent UK study
identified that 5% of females aged 19-64 had an intake of vitamin A below the
lower reference intake, likewise 12% with riboflavin, 23% iron, 8% calcium, 11%
magnesium 23% potassium, 4% zinc, 51% selenium, 10% iodine and 21% had a low
vitamin D status [153]. 16% of females in the same age group were considered to
have folate concentrations below World Health Organisation threshold indicative
of folate deficiency, and the proportion of women of childbearing age with red
blood cell concentrations of folate below the threshold for elevated risk of
neural tube defects (748 nmol/L) was 91% [154].
Folate metabolism and
genotype
The enzyme 5, 10-methylenetetrahydrofolate reductase (MTHFR) is critical
in folate metabolism. It converts 5,10-methylenetetrahydrofolate to
5-methyltetrahydrofolate, the primary form of folate in the circulation and
operates as a methyl donor in homocysteine Hcy) conversion to methionine [155].
A C677T polymorphism in the MTHFR gene limits the activity of this enzyme and
can cause enhanced thermolability, especially in states of folate deficiency
[156]. Mutation homozygous individuals have significantly lower plasma folate
levels and elevated plasma Hcy [41,157,158]. It is not surprising that the
MTHFR 677T mutation is associated with a higher risk of NTDs [159]. As a result
of the recognised relationship between NTDs and suboptimal folate status, many
nations have adopted mandatory fortification of the vitamin in products,
usually of a cereal grain origin [160]. This has resulted in increased levels
of serum folate and consequently lower Hcy concentrations [161,162] and reduced
rates of NTDs [163,164] at the population level, but there are still some
subgroups, particularly fertile young females, with an ongoing suboptimal
intake of folate despite this fortification and ready access to vitamin
supplements [165,166]. Uncertainty remains regarding optimal folate intake for
those carrying MTHFR 677TT polymorphism, which probably require an increased
levels, especially where folate status is already low [167]. Studies of men of
Mexican-American origin suggested that 400 mcg of dietary folate equivalents
per day (where, 1mcg DFE=1 mcg food folate or 600 mcg folic acid with food) was
inadequate for TT subjects [168,169]. Therefore, in pregnancy recommended
intakes vary from country to country from 355 to 800 μg/day dietary folate
equivalents [170], with a number of authorities taking genetic susceptibility
to suboptimal status of folate into consideration. Hence, in Australia, the
recommended dietary intake for pregnancy is 600 μg/day DFEs [171]; whilst for
women with an increased risk of NTDs at birth and folate deficiency, the South
Australian Perinatal Practice Guidelines make a recommendation of a daily total
folate intake of 5mgs. Here, high risk is deemed to include those with an
identified MTHFR polymorphism [172]. This is supported by a 2017 meta-analysis
that confirms a MTHFR TT genotype to be associated with lowered serum folate
levels, increased plasma homocysteine as well as a reduced response to
supplementation at daily doses from 400 mcg over short term time periods [173].
Folic acid, neural
tube defects and small-for-gestational age neonates
The benefit of folic acid supplementation in preventing NTDs, including
anencephaly, encephalocoele and spina bifida, is now accepted [174-176]. Within
the first month of conception, the neural tube closes and if this closure is
incomplete, this leads to NTDs [177], with folic acid thought to be essential
in this process. As a result the UK Department of Health recommended in 1992,
that females intending to become pregnant should increase their intake of
folate by an additional 400 mcg daily from preconception until 12 weeks of
gestation to be accomplished through the increased consumption of folate rich
foods and/or taking a supplement delivering 400 mcg folic acid, with the latter
emphasised as the most important [178].
A 2009 study sought to examine the success of this recommendation in an
inner city setting [179] in pregnant women in their first trimester. Whereas
76% of the cohort reported consuming supplements containing the vitamin
throughout the first trimester of pregnancy, only 12% commenced preconception,
and only 17% started use before neural tube closure. This situation was
similarly reflected in a later UK study in 466,860 females who had attended
antenatal screening for NTDs and Down’s syndrome [180]. The proportion of those
women optimising their diet with the vitamin in supplement form before
pregnancy reduced to 31% in 2011-2012 from 35% in 1999-2001. Of women aged
below 20, only 6% used supplements containing folic acid prior to pregnancy, in
comparison to 40% of those aged 35-39, with significant social and cultural
differences also identified. Of those females who had previously experienced an
NTD pregnancy, before their current pregnancy, only 51% reported taking folic
acid supplements.
A 2016 UK study investigated the prevalence of pregnancies with NTDs and
attempted to quantify those incidences that might have been preventable had
fortification of folic acid been pursued [155]. It concluded that in the two
decades from found that from 1991, the incidence of NTD pregnancies was 1.28
per 1000 total births. This was characterised by 81% terminations, 19% live
births, with 0.5% stillbirths and fetal deaths at 20 weeks or more gestation.
It estimated in UK, had the fortification of folic acid been followed at levels
recommended in USA from 1998 onwards, around 2014 less NTD pregnancies might
have resulted and concludes “failure to implement folic acid fortification in
the UK has caused, and continues to cause, avoidable terminations of pregnancy,
stillbirths, neonatal deaths and permanent serious disability in surviving
children”.
A 2015 meta-analysis and systematic review of UK data assessed the risk
of neonates being small for gestational age according to the timing of
initiation of folic acid supplementation. It identified that of the pregnancies
where folic acid supplementation was recorded, when it was initiated before
conception in 25.5% of cases. It concluded, supplementation significantly
reduces the risk of small-for-gestational age at birth, but only if commenced
pre-conceptually [181].
CONCLUSION
Literature from as far back as the 1970s clearly demonstrates that OCs
induce depletions of a number of vitamins, minerals and other nutrients. More
recent data suggests a negative impact of OCs upon vitamin B6, folate, vitamin
B12, zinc, selenium, magnesium [13,48-50,54,65,67], even when lower dose
formulations are taken into consideration. In UK, the most recent National Diet
and Nutrition Survey published in January 2019, indicates little has changed in
terms of improvement in the nutritional status of females of a child bearing
age, with folate intake reducing by 5 mcg/day during the latest period under
review, in this cohort and with a similarly low consumption of foods rich in
vitamin B12, magnesium, selenium and zinc as in the previous report [182].
As already highlighted, there are significant numbers of women of
childbearing age with an inadequate intake of folic acid in the UK, along with
considerable variation in attitudes to pre-conceptual use of supplements
containing the vitamin. Furthermore, given the high rate of unplanned
pregnancies whilst females are taking OCs, as well as the likelihood that any
pregnancy which might occur within 3 months of discontinuing the drug could do
so in a state of a less than optimal folate status, it would appear that folic
acid supplementation is the minimal intervention that might be considered for
users of OCs, especially in countries which do not implement fortification of
foods, such as UK. There are still around 1000 pregnancies with a diagnosis of
NTD occurring in UK and around 80% of these ending in termination [183] and it
is highly possible that an improved level of compliance with folic acid
supplementation concurrent with OC usage would more than likely impact
positively on this unsatisfactory situation.
1. Brunton
LL, Blumenthal D, Murri N, Dandan R, Knollmann B (2011) In: Goodman &
Gilman's The Pharmacological Basis of Therapeutics. XII Edn. New York.
2. Lobo
R, Stanczyk F (1994) New knowledge in the physiology of hormonal
contraceptives. Am J Obstet Gynecol 170: 1499-1507.
3. Shulman
LP (2011) The state of hormonal contraception today: benefits and risks of
hormonal contraceptives: combined estrogen and progestin contraceptives. Am J
Obstet Gynecol 205: S9-13.
4. Mansour
D, Inki P, Gemzell-Danielsson K (2010) Efficacy of contraceptive methods: A
review of the literature. Eur J Contracept Reprod Health Care 15: 4-16.
5. Bitzer
J, Simon J (2011) Current issues and available options in combined hormonal
contraception Contraception 84: 342-356.
6. Gallo
M, Nanda K, Grimes D, Lopez L, Schulz K (2008) 20 µg versus >20 µg estrogen
combined oral contraceptives for contraception. Cochrane Database Syst Rev.
7. Theuer
RC (1972) Effect of oral contraceptive agents on vitamin and mineral needs: A
review J Reprod Med 8: 13-19.
8. Berg
G, Kohlmeier L, Brenner H (1998) Effect of oral contraceptive progestins on
serum copper concentration. Eur J Clin Nutr 52: 711-715.
9. Ghayour-Mobarhan
M, Taylor A, New SA, Lamb DJ, Ferns GA (2005) Determinants of serum copper,
zinc and selenium in healthy subjects. Ann Clin Biochem 42: 364-375.
10. Tamura
T, Picciano MF (2006) Folate and human reproduction. Am J Clin Nutr 83: 993-1016.
11. Mrc
Vitamin Study Research Group (1991) Prevention of neural tube defects: Results
of the Medical Research Council Vitamin Study. Lancet 338: 131-137.
12. Prasad
AS, Oberleas D, Moghissi KS, Stryker JC, Lei KY (1975) Effect of oral
contraceptive agents on nutrients: Ii Vitamins. Am J Clin Nutr 28: 385-391.
13. Wilson
SM, Bivins BN, Russell KA, Bailey LB (2011) Oral contraceptive use: Impact on
folate, vitamin B6 and vitamin B12. Status Nutr Rev 69: 572-583.
14. Mooij
PN, Thomas CM, Doesburg WH, Eskes TK (1991) Multivitamin supplementation in
oral contraceptive users. Contraception 44: 277-288.
15. Tyrer
LB (1984) Nutrition and the pill. J Reprod Med 29: 547-550.
16. Ahmed
F, Bamji MS, Iyengar L (1975) Effect of oral contraceptive agents on vitamin
nutrition status Am J Clin Nutr 28: 606-615.
17. Thorp
VJ (1980) Effect of oral contraceptive agents on vitamin and mineral
requirements J Am Diet Assoc 76: 581-584.
18. Briggs
MH, Briggs M (1975) Thiamine status and oral contraceptives. Contraception 11:
151-154.
19. Vir
SC, Love AH (1979) Effect of oral contraceptive agents on thiamin status. Int J
Vitamin Nutr Res 49: 291-295.
20. Lewis
CM, King JC (1980) Effect of oral contraceptives agents on thiamin, riboflavin
and pantothenic acid status in young women. Am J Clin Nutr 33: 832-838.
21. Ahmed
F, Bamji MS (1976) Vitamin supplements to women using oral contraceptives
(studies of vitamins B1, B2, B6 and A). Contraception 14: 309-318.
22. Newman
LJ, Lopez R, Cole HS, Boria MC, Cooperman JM (1978) Riboflavin deficiency in
women taking oral Contraceptive agents. Am J Clin Nutr 31: 247-249.
23. Sanpitak
N, Chayutimonkul L (1974) Oral contraceptives and riboflavine nutrition. Lancet
303: 836-837.
24. Bamji
M, Prema K, Jacob C, Rani M, Samyukta D (1985) Vitamin supplements to Indian
women using low dosage oral contraceptives. Contraception 32: 405-416.
25. Roe
DA, Bogusz S, Sheu J, McCormick DB (1982) Factors affecting riboflavin
requirements of oral contraceptive users and nonusers. Am J Clin Nutr 35:
495-501.
26. Zencirci
B (2010) Comparison of the effects of dietary factors in the management and
prophylaxis of migraine. J Pain Res 3: 125-130.
27. Matsui
MS, Rozovski SJ (1982) Drug-nutrient interaction. Clin Ther 4: 423-440.
28. Prasad
AS, Lei KY, Moghissi KS, Stryker JC, Oberleas D (1976) Effect of oral
contraceptives on nutrients. III. Vitamins B6, B12 and folic acid. Am J Obstet
Gynecol 125: 1063-1069.
29. Butterworth
CE (1973) Interactions of nutrients with oral contraceptives and other drugs. J
Am Diet Assoc 62: 510-514.
30. Haspels
AA, Bennink HJ, Schreurs WH (1978) Disturbance of tryptophan metabolism and its
correction during oestrogen treatment in postmenopausal women. Maturitas 1:
15-20.
31. Rose
DP (1966) The influence of estrogens on tryptophan metabolism in man. Clin Sci
31: 265- 272.
32. Lussana
F, Zighetti Ml, Bucciarelli P, Cugno M, Cattane M (2003) Blood levels of
homocysteine, folate, vitamin B6 and B12 in women using oral contraceptives
compared to non-users. Thromb Res 112: 37-41.
33. Lumeng
L, Cleary Re, Li Tk (1974) Effect of oral contraceptives on the plasma
concentration of pyridoxal phosphate. Am J Clin Nutr 27: 326-333.
34. Morris
Ms, Picciano Mf, Jacques Pf, Selhub J (2008) Plasma pyridoxal 5'-phosphate in
the US population: The National Health and Nutrition Examination Survey,
2003-2004. Am J Clin Nutr 87: 1446-1454.
35. Leklem
JE, Brown RR, Rose DP, Linkswiler HM (1975) Vitamin B6 requirements of women
using oral contraceptives. Am J Clin Nutr 28: 535-541.
36. Leklem
JE (1986) Vitamin B-6 requirement and oral contraceptive use - A concern? J
Nutr 116: 475-477.
37. van
der Vange N, van der Berg H, Kloosterboer HJ, Haspels AA (1989) Effects of
seven low-dose combined contraceptives on vitamin B6 status. Contraception 40:
377-384.
38. Miller
LT (1986) Do oral contraceptive agents affect nutrient requirements - Vitamin B6?
J Nutr 116: 1344-1345.
39. Trowbridge
M Jr, Wadsworth R, Moffitt E (1968) Malabsorption associated with gluten
enteropathy, do oral contraceptives interfere with folate metabolism? J Maine
Med Assoc 59: 240-242.
40. Paton
A (1969) Oral contraceptives and folate deficiency. Lancet 1: 418.
41. Ryser
J, Farquet J, Petite J (1971) Megaloblastic anemia due to folic acid deficiency
in a young woman on oral contraceptives. Acta Hematol 45: 319-324.
42. Whitehead
N, Reyner F, Lindenbaum J (1973) Megaloblastic changes in the cervical
epithelium. Association with oral contraceptive therapy and reversal with folic
acid. JAMA 226: 1421-1424.
43. Shojania
AM (1982) Oral contraceptives: Effect of folate and vitamin B12 metabolism. Can
Med Assoc J 126: 244-247.
44. Shojania
AM, Hornady G, Barnes P (1968) Oral contraceptives and serum-folate level.
Lancet 1: 1376-1377.
45. Pritchard
JA, Scott DE, Whalley PJ (1971) Maternal folate deficiency and pregnancy
wastage. IV. Effects of folic acid supplements, anticonvulsants and oral
contraceptives. Am J Obstet Gynecol 109: 341-346.
46. Castren
OM, Rossi RR (1970) Effect of oral contraceptives on serum folic acid content.
J Obstet Gynecol Br Commonw 77: 548-550.
47. Green
TJ, Houghton LA, Donovan U, Gibson R, O’Connor DL (1998) Oral contraceptives
did not affect biochemical folate indexes and homocysteine concentrations in
adolescent females. J Am Diet Assoc 98: 49-55.
48. Shere
M, Bapat P, Nickel C, Kapur B, Koren G (2015) Association between use of oral
contraceptives and folate status: A systematic review and meta-analysis. J
Obstet Gynecol Can 37: 430-8.
49. Castano
PM, Aydemir A, Sampson-Landers C, Lynen R (2014) The folate status of
reproductive-aged women in a randomised trial of a folate-fortified oral
contraceptive: dietary and blood assessments. Public Health Nutr 17: 1375-1383.
50. Fruzzetti
F, Beyaz P (2012) An oral contraceptive fortified with folate. Womens Health 8:
13-19.
51. Butterworth
CE, Hatch KD, Gore H, Mueller H, Krumdieck C (1982) Improvement in cervical
dysplasia associated with folic acid therapy in users of oral contraceptives.
Am J Clin Nutr 35: 73-82.
52. Check
WA (1980) Folate for oral contraceptive users may reduce cervical cancer risk.
J Am Med Assoc 244: 633-634.
53. Wertalik
LF, Metz EN, Lobuglio AF, Balcerzak SP (1972) Decreased serum B 12 levels with
oral contraceptive use. JAMA 221: 1371-1374.
54. Sutterlin
M, Bussen S, Rieger L, Dietl J, Steck T (2003) Serum folate and vitamin B12 levels
in women using modern oral contraceptives (Oc) containing 20 µg ethinyl
estradiol. Eur J Obstet Gynecol Reprod Biol 107: 57-61.
55. Riedel
B, Bjorke Monsen A, Ueland P, Schneede J (2005) Effects of oral contraceptives
and hormone replacement therapy on markers of cobalamin status. Clin Chem 51:
778-781.
56. Shojania
AM, Wylie B (1979) The effect of oral contraceptives on vitamin B12 metabolism.
Am J Obstet Gynecol 135: 129-134.
57. Veninga
KS (1984) Effects of oral contraceptives on vitamins B6, B12, C and folacin. J
Nurse Midwifery 29: 386-390.
58. Hielt
K, Brynskov J, Hippe E, Lundström P, Munck O (1985) Oral contraceptives and the
cobalamin (vitamin B12) metabolism. Acta Obstet Gynecol Scand 64: 59-63.
59. Grace
E, Emans SJ, Drum DE (1982) Hematologic abnormalities in adolescents who take
oral contraceptive pills. J Pediatrics 101: 771-774.
60. Barone
C, Bartoloni C, Ghirlanda G, Gentiloni N (1979) Megaloblastic anemia due to
folic acid deficiency after oral contraceptives. Hematologica 64: 190-195.
61. McArthur
JO, Tang H, Petocz P, Samman S (2013) Biological variability and impact of oral
contraceptives on vitamins B6, B12 and folate status in women of reproductive
age. Nutrients 5: 3634-3645.
62. Adams
MJ Jr, Khoury MJ, Scanlon KS, Stevenson RE, Knight GJ, et al. (1995) Elevated mid-trimester
serum methylmalonic acid levels as a risk factor for neural tube defects.
Teratology 51: 311-317.
63. Gardyn
J, Mittelman M, Zlotnik J, Sela BA, Cohen AM (2000) Oral contraceptives can
cause falsely low vitamin B12 levels. Acta Hematol 104: 22-24.
64. Bush
AI (2003) The metallobiology of Alzheimer's disease. Trends Neurosci 26:
207-214.
65. Dante
G, Vaiarelli A, Facchinetti F (2014) Vitamin and mineral needs during the oral
contraceptive therapy: A systematic review. Int J Reprod Contracept Obstet
Gynecol 3: 1-10.
66. Basnayake
S, de Silva SV, Miller PC, Rogers S (1983) A trial of daily vitamin
supplementation as a means of reducing oral contraceptive side effects and
discontinuation in Sri Lanka. Contraception 27: 465-472.
67. Palmery
A, Saraceno A, Vaiarelli G, Carlomagno (2013) Oral contraceptives and changes
in nutritional requirements. Eur Rev Med Pharmacol Sci 17: 1804-1813.
68. Webb
JL (1980) Nutritional effects of oral contraceptive use: A review. J Reprod Med
25: 150-156.
69. WHO (1975)
Advances in Methods on Fertility Regulation. World Health Organization.
70. Hudiburgh
N, Milner A (1979) Influence of oral contraceptives on ascorbic acid and
triglyceride status. J Am Diet Assoc 75: 19-22.
71. Zal
F, Mostafavi-Pour Z, Amini F, Heidari A (2012) Effect of vitamin E and C
supplements on lipid peroxidation and GSH-dependent antioxidant enzyme status
in the blood of women consuming oral contraceptives Contraception 86: 62-66.
72. Weininger
J, King JC (1977) Effect of oral contraceptives on ascorbic acid status of
young women consuming a constant diet Nutr Rep Int 15: 255-264.
73. Vihtamaki
T, Parantainen J, Koivisto AM, Metsä-Ketelä T, Tuimala R (2002) Oral ascorbic
acid increases plasma estradiol during postmenopausal hormone replacement
therapy. Maturitas 42: 129-35.
74. Aftergood
L, Alfin-Slater RB (1974) Oral contraceptive alpha-tocopherol
interrelationships. Lipids 9: 91-96.
75. Akinsanya
M, Adeniyi T, Ajayi G, Oyedele M (2010) Effects of vitamin E and folic acid on
some antioxidant enzymes activities of female Wistar rats administered combined
oral contraceptives. Afr J Biochem Res 4: 238-242.
76. Brigg
M (1975) Letter: Vitamin E status and oral contraceptives. Am J Clin Nutr 28:
436.
77. Renaud
S, Ciavatti M, Perrot L, Berthezene F, Dargent D, et al. (1987) Influence of
vitamin E administration on platelet functions in hormonal contraceptive users.
Contraception 36: 347-358.
78. Seelig
MS (1990) Increased need for magnesium with the use of combined estrogen and
calcium for osteoporosis treatment Magnes Res 3: 197-215.
79. Seelig
MS (1993) Interrelationship of magnesium and estrogen in cardiovascular and
bone disorders, eclampsia, migraine and premenstrual syndrome. J Am Coll Nutr
12: 442-458.
80. Muneyyirci-Delale
O, Nacharaju VL, Dalloul M, Altura BM, Altura BT (1999) Serum ionized magnesium
and calcium in women after menopause: Inverse relation of estrogen with ionized
magnesiu. Fertil Steril 71: 869-872.
81. Stanton
MF, Lowenstein FW (1987) Serum magnesium in women during pregnancy, while
taking contraceptives and after menopause. J Am Coll Nutr 6: 313-319.
82. Akinloye
O, Adebayo T, Oguntibeju O, Oparinde D, Ogunyemi E (2011) Effects of
contraceptives on serum trace elements, calcium and phosphorus levels. West
Indian Med J 60: 308-315.
83. Hameed
A, Majeed T, Rauf S, Ashraf M, Jalil M, et al. (2001) Effect of oral and
injectable contraceptives on serum calcium, magnesium and phosphorus in women.
J Ayub Med Coll Abbottabad 13: 24-25.
84. Olatunbosun
D, Adeniyi F, Adadevoh BK (1974) Effect of oral contraceptives on serum magnesium
levels. Int J Fertil 19: 224-226.
85. Blum
M, Kitai E, Ariel Y, Schnierer M, Bograd H (1991) Oral contraceptive lowers
serum magnesium. Harefuah 121: 363-364.
86. Cowan
JA (1995) Introduction to the biological chemistry of magnesium. Edr. Cowan JA.
New York. VCH.
87. Halsted
JA, Hackley BM, Smith JC Jr (1968) Plasma-zinc and copper in pregnancy and
after oral contraceptives. Lancet 2: 278-279.
88. King
JC (1987) Do women using oral contraceptive agents require extra zinc? J Nutr
117: 217-219.
89. Briggs
MH, Briggs M, Austin J (1971) Effects of steroid pharmaceuticals on plasma zinc.
Nature 232: 480-481.
90. Prema
K, Ramalakshmi BA, Babu S (1980) Serum copper and zinc in hormonal
contraceptive users. Fertil Steril 33: 267-271.
91. Fallah
S, Sani Fv, Firoozrai M (2009) Effect of contraceptive pill on the selenium and
zinc status of healthy subjects. Contraception 80: 40-43.
92. Chilvers
DC, Jones MM, Selby PL, Dawson JB, Hodgkinson A (1985) Effects of oral ethinyl
oestradiol and norethisterone on plasma copper and zinc complexes in
post-menopausal women. Hormone Metab Res 17: 532-535.
93. Smith
JC, Brown ED (1976) Effects of oral contraceptive agents on trace element
metabolism - A review In: Prasad AS (ed) Trace Elements in Human Health and
Disease Vol. II, Essential and Toxic Elements. New York: Academic Press, pp: 315-345.
94. Vir
SC, Love AH (1981) Zinc and copper nutriture of women taking oral contraceptive
agents. Am J Clin Nutr 34: 1479-1483.
95. Hinks
LJ, Clayton BE, Lloyd RS (1983) Zinc and copper concentrations in leukocytes
and erythrocytes in healthy adults and the effect of oral contraceptives. J
Clin Pathol 36: 1016-1021.
96. Powell-Beard
L, Lei KY, Shenker L (1987) Effect of long-term oral contraceptive therapy
before pregnancy on maternal and fetal zinc and copper status. Obstet Gynecol
69: 26-32.
97. Liukko
P, Erkkola R, Pakarinen P, Järnström S, Näntö V, et al. (1988) Trace elements
during 2 year’s oral contraception with low-estrogen preparations. Gynecol
Obstet Invest 25: 113-117.
98. Thane
CW, Christopher JB, Ann Prentice (2002) Oral contraceptives and nutritional
status in adolescent British girls. Nutr Res 22: 449-462.
99. Gambacciani
M, Cappagli B, Lazzarini V, Ciaponi M, Fruzzetti F, et al. (2006) Longitudinal
evaluation of perimenopausal bone loss: Effects of different low dose oral
contraceptive preparations on bone mineral density. Maturitas 54: 176-180.
100.Kleerekoper
M, Brienza RS, Schultz LR, Johnson CC (1991) Oral contraceptive use may protect
against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research
Group. Arch Intern Med 151: 1971-1976.
101.Kuohung
W, Borgatta L, Stubblefield P (2000) Low-dose oral contraceptives and bone
mineral density: An evidence-based analysis. Contraception 61: 77-82.
102.Liu
SL, Lebrun CM (2006) Effect of oral contraceptives and hormone replacement
therapy on bone mineral density in premenopausal and peri-menopausal women: A
systematic review. Br J SportsMed 40: 11-24.
103.
Garnero P, Sornay-Rendu E, Delmas PD (1995) Decreased bone turnover in oral
contraceptive users. Bone 16: 499-503.
104.Zittermann
A (2000) Decreased urinary calcium loss and lower bone turnover in young oral
contraceptive users. Metabolism 49: 1078-1082.
105.Goulding
A, Mc Chesney R (1977) Oestrogen-progestogen oral contraceptives and urinary
calcium excretion. Clin Endocrinol 6: 449-454.
106.Hartard
M, Kleinmond C, Kirchbichler A, Jeschke D, Wiseman M, et al. (2004) Age at
first oral contraceptive use as a major determinant of vertebral bone mass in
female endurance athletes. Bone 35: 836-841.
107.Cobb
KL, Kelsey JL, Sidney S, Ettinger B, Lewis CE (2002) Oral contraceptives and
bone mineral density in white and black women in CARDIA (Coronary Risk
Development in Young Adults) Osteoporos Int 13: 893-900.
108.Hartard
M, Bottermann P, Bartenstein P, Jeschke D, Schwaiger M (1997) Effects on bone
mineral density of low-dosed oral contraceptives compared to and combined with
physical activity. Contraception 55: 87-90.
109.Burr
DB, Yoshikawa T, Teegarden D, Lyle R, Mc Cabe G, et al. (2000) Exercise and
oral contraceptive use suppress the normal age-related increase in bone mass
and strength of the femoral neck in women 18-31 years of age. Bone 27: 855-863.
110.Weaver
CM, Teegarden D, Lyle RM, Mc Cabe GP, Mc Cabe LD, et al. (2001) Impact of
exercise on bone health and contraindication of oral contraceptive use in young
women. Med Sci Sports Exerc 33: 873-880.
111.Teegarden
D, Legowski P, Gunther CW, Mc Cabe GP, Peacock M, et al. 2005) Dietary calcium
intake protects women consuming oral contraceptives from spine and hip bone
loss. J Clin Endocrinol Metab 90: 5127-5133.
112.Babić
Z, Tariba B, Kovačić J, Pizent A, Varnai V, et al. (2013) Relevance of serum
copper elevation induced by oral contraceptives: A meta-analysis. Contraception
87: 790-800.
113.Palan
PR, Strube F, Letko J, Sadikovic A, Mikhail MS (2010) Effects of oral, vaginal
and transdermal hormonal contraception on serum levels of coenzyme Q10, vitamin
E and total antioxidant activity. Obstet Gynecol Int.
114.Palan
PR, Connell K, Ramirez E, Inegbenijie C, Gavara RY (2005) Effects of menopause
and hormone replacement therapy on serum levels of coenzyme Q10 and other
lipid-soluble antioxidants. Biofactors 25: 61-66.
115.Knopp
RH, Zhu X, Bonet B (1994) Effects of estrogens on lipoprotein metabolism and
cardiovascular disease in women. Atherosclerosis 110: S83-91.
116.Palan
PR, Romney SL, Vermund SH, Mikhail MG, Basu J (1989) Effects of smoking and
oral contraception on plasma β-carotene levels in healthy women. Am J Obstet
Gynecol 161: 881-885.
117.United
Nations, Department of Economic & Social Affairs, Population Division (2012)
World contraceptive use.
118.World
Health Organization, Department of Reproductive Health and Research (WHO/RHR),
Johns Hopkins Bloomberg School of Public Health Center for Communication
Programs (CCP) (2011) Knowledge for health project. Family planning: A global
handbook for providers (2011 update). Baltimore and Geneva: CCP and WHO. 388.
119.Office
for National Statistics Opinions (2008/2009) Survey Report No. 41.
Contraception and Sexual Health.
120.Rashed
AN, Hsia Y, Wilton L, Ziller M, Kostev K, et al. (2015) Trends and patterns of
hormonal contraceptive prescribing for adolescents in primary care in the UK. J
Fam Plann Reprod Health Care 41: 216-222.
121.http://www.theguardian.com/society/2010/dec/03/hormone-implants-contraception-condoms
122.http://informahealthcare.com/doi/pdf/10.1080/13625180410001715681
123.Singh
S, Sedgh G, Hussain R (2010) Unintended pregnancy: Worldwide levels, trends and
outcomes. Stud Fam Plann 41: 241-250.
124.Khosravi
A, Najafi F, Rahbar MR (2009) Health indicators in I.R. Iran Tehran: Ministry
of Health and Medical Education. Available at: http://behdasht.gov.ir/uploads/291_1041_simayeisalamat.Pdf
125.Moosazadeh
M, Nekoei-Moghadam M, Emrani Z, Amiresmaili M (2014) Prevalence of unwanted
pregnancy in Iran: A systematic review and meta-analysi. Int J Health Plan
Manag 29: e277-290.
126.Ali
MM, Cleland JG, Shah, Iqbal H (2012) Causes and consequences of contraceptive
discontinuation: Evidence from 60 demographic and health surveys. Cairo: WHO.
127.de
Leon RP, Juarez-Perez MA, Grubb GS (1997) Effect of vitamin B6 on the side
effects of a low-dose combined oral contraceptive. Contraception 55: 245-248.
128.Mohammad-Alizadeh-Charandabi
S, Mirghafourvand M, Froghy L, Javadzadeh Y, Razmaraii N (2015) The effect of
multivitamin supplements on continuation rate and side effects of combined oral
contraceptives: A randomised controlled trial. Eur J Contracept Reprod Healthc
20: 361-371.
129.Zolfaghari
SS (2016) The relationship between folic acid, vitamin B12 and vitamin B6 intakes
and depression in women who use hormonal oral contraceptives thesis presented
to the Department of Family and Consumer Sciences, California State University,
Long Beach BS 2005, University of California, Irvine.
130.Westhoff
CL, Heartwell S, Edwards S, Zieman M, Stuart G, et al. (2007) Oral
contraceptive discontinuation: Do side effects matter? Am J Obstet Gynecol 196:
412.e1-e7.
131.Oakley
D, Sereika S, Bogue EL (1991) Oral contraceptive pill use after an initial
visit to a family planning clinic. Fam Plann Perspect 23: 150-154.
132.Rosenberg
MJ, Waugh MS, Meehan TE (1995) Use and misuse of oral contraceptives: Risk indicators
for poor pill taking and discontinuation. Contraception 51: 283-288.
133.Rosenberg
MJ, Waugh MS (1998) Oral contraceptive discontinuation: A prospective
evaluation of frequency and reasons. Am J Obstet Gynecol 179: 577-582.
134.Berenson
AB, Rahman M (2009) Changes in weight, total fat, percent body fat and
central-to-peripheral fat ratio associated with injectable and oral
contraceptive use. Am J Obstet Gynecol 200: 329.e1-e8.
135.de Melo
N, Aldrighi J, Faggion D, Reyes V, Souza J, et al. (2004) A prospective
open-label study to evaluate the effects of the oral contraceptive Harmonet1
(gestodene75/EE20) on body fat. Contraception 70: 65-71.
136.Gallo
M, Lopez L, Grimes D, Schulz K, Helmerhorst F (2014) Combination
contraceptives: Effects on weight (Review). Cochrane Database Syst Rev 78.
137.Picardo
CM, Nichols M, Edelman A, Jensen JT (1972) (2002) Women’s knowledge and sources
of information on the risks and benefits of oral contraception. J Am Med Womens
Assoc 58: 112-116.
138.García
OP, Long KZ, Rosado JL (2009) Impact of micronutrient deficiencies on obesity.
Nutr Rev 67: 559-572.
139.Aasheim
ET, Hofsø D, Hjelmesæth J, Birkeland KI, Bøhmer T (2008) Vitamin status in
morbidly obese patients: A cross-sectional study. Am J Clin Nutr 87: 362-369.
140.Kimmons
JE, Blanck HM, Tohill BC, Zhang J, Khan LK (2006) Associations between body
mass index and the prevalence of low micronutrient levels among US adults.
Medscape Gen Med 8: 59.
141.Park
B, Kim J (2016) Oral contraceptive use, micronutrient deficiency and obesity
among premenopausal females in Korea: The necessity of dietary supplements and
food intake improvement. PloS One 11: e0158177.
142.Kowalska
K, Milnerowicz H (2016) Pro/antioxidant status in young healthy women using
oral contraceptives. Environ Toxicol Pharmacol 43: 1-6.
143.Kamp
F, Soares T, Rodrigues L, Donangelo C (2011) Effect of oral contraceptive use
and zinc supplementation on zinc, iron and copper biochemical indices in young
women e-SPEN. Eur J Clin Nutr Metab 6: e253-e258.
144.Bernstein
P, Pohost G (2010) Progesterone, progestins and the heart. Rev Cardiovasc Med
11: 228-236.
145.Kiriwat
O, Petyim S (2010) The effects of transdermal contraception on lipid profiles,
carbohydrate metabolism and coagulogram in Thai women. Gynecol Endocrinol 26:
361-365.
146.Grigoryan
OR, Grodnitskaya EE, Andreeva EN, Shestakova MV, Melnichenko GA, et al. (2006)
Contraception in perimenopausal women with diabetes mellitus. Gynecol
Endocrinol 22: 198- 206.
147.Minozzi
M, Costantino D, Guaraldi C, Unfer V (2011) The effect of a combination therapy
with myo-inositol and a combined oral contraceptive pill versus a combined oral
contraceptive pill alone on metabolic, endocrine and clinical parameters in
polycystic ovary syndrome. Gynecol Endocrinol 27: 920-924.
148.Plu-Bureau
G, Hugon-Rodin J, Maitrot-Mantelet L, Canonico M (2013) Hormonal contraceptives
and arterial disease: an epidemiological update. Best Pract Res Clin Endocrinol
Metab 27: 35-45.
149.Dilbaz
B, Ozdegirmenci O, Caliskan E, Dilbaz S, Haberal A (2010) Effect of
etonogestrel implant on serum lipids, liver function tests and hemoglobin
levels. Contraception 81: 510-514.
150.Scharnagl
H, Petersen G, Nauck M, Teichmann AT, Wieland H, et al. (2004) Double-blind,
randomized study comparing the effects of two monophasic oral contraceptives
containing ethinylestradiol (20 µg or 30 µg) and levonorgestrel (100 µg or 150 µg)
on lipoprotein metabolism. Contraception 69: 105-113.
151.Skouby
SO, Endrikat J, Dusterberg B, Schmidt W, Gerlinger C, et al. (2005) A 1 year
randomized study to evaluate the effects of a dose reduction in oral contraceptives
on lipids and carbohydrate metabolism: 20 µg ethinyl estradiol combined with
100 µg levonorgestrel. Contraception 71: 111-117.
152.Torkzahrani
S, Heidari A, Mostafavi-pour Z, Ahmadi M, Zal F (2014) Amelioration of lipid
abnormalities by vitamin therapy in women using oral contraceptives. Clin Exp
Reprod Med 41: 15-20.
153.NDNS
(2016) Results from years 7-8 (combined) of the rolling programme (2014/2015-2015/2016).
UK Public Health, England.
154.Morris
JK, Rankin J, Draper ES, Kurinczuk JJ, Springett A, et al. (2016) Prevention of
neural tube defects in the UK: A missed opportunity. Arch Dis Childhood 101:
604-607.
155.Lim
U, Wang SS, Hartge P, Cozen W, Kelemen LE, et al. (2007) Gene-nutrient
interactions among determinants of folate and one-carbon metabolism on the risk
of non-Hodgkin lymphoma: NCI-SEER case-control study. Blood 109: 3050-3059.
156.Ogino
S, Wilson RB (2003) Genotype and haplotype distributions of MTHFR 677C>T and
1298A>C single nucleotide polymorphisms: A meta-analysis. J Hum Genet 48:
1-7.
157.Malinow
MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, et al (1997) The effects of folic
acid supplementation on plasma total homocysteine are modulated by multivitamin
use and methylene tetrahydrofolate reductase genotypes. Arteriosclerosis, Thrombosis
and Vascular Biology 17: 1157-1162.
158.Yang
QH, Botto LD, Gallagher M, Friedman JM, Sanders CL, et al. (2008) Prevalence
and effects of gene-gene and gene-nutrient interactions on serum folate and
serum total homocysteine concentrations in the United States: Findings from the
third National Health and Nutrition Examination Survey DNA Bank. Am J Clin Nutr
88: 232-246.
159.Yadav
U, Kumar P, Yadav SK, Mishra OP, Rai V (2015) Polymorphisms in folate
metabolism genes as maternal risk factor for neural tube defects: An updated
meta-analysis. Metab Brain Dis 30: 7-24.
160.To
QG, Chen TT, Magnussen CG, To KG (2013) Workplace physical activity
interventions: A systematic review. Am J Health Promot 27: e113-123.
161.Pfeiffer
CM, Caudill SP, Gunter EW, Osterloh J, Sampson EJ (2005) Biochemical indicators
of B vitamin status in the US population after folic acid fortification: Results
from the National Health and Nutrition Examination Survey 1999-2000. Am J Clin Nutr
82: 442-450.
162.Hickling
S, Hung J, Knuiman M, Jamrozik K, Mc Quillan B, et al. (2005) Impact of
voluntary folate fortification on plasma homocysteine and serum folate in
Australia from 1995 to 2001: A population based cohort study. J Epidemiol
Community Health 59: 371-376.
163.Williams
LJ, Mai CT, Edmonds LD, Shaw GM, Kirby RS, et al. (2002) Prevalence of spina
bifida and anencephaly during the transition to mandatory folic acid
fortification in the United States. Teratology 66: 33-39.
164.de Wals
P, Tairou F, Van Allen MI, Uh SH, Lowry RB, et al. (2007) Reduction in
neural-tube defects after folic acid fortification in Canada. N Engl J Med 357:
135-142.
165.Mallard
SR, Gray AR, Houghton LA (2012) Peri-conceptional bread intakes indicate New
Zealand’s proposed mandatory folic acid fortification program may be outdated: Results
from a postpartum survey. BMC Pregnancy Childbirth 12: 8.
166.Yang
QH, Carter HK, Mulinare J, Berry RJ, Friedman JM, et al. (2007) Race-ethnicity
differences in folic acid intake in women of childbearing age in the United
States after folic acid fortification: Findings from the National Health and
Nutrition Examination Survey, 2001-2002. Am J Clin Nutr 85: 1409-1416.
167.Nagele
P, Meissner K, Francis A, Födinger M, Saccone NL (2011) Genetic and
environmental determinants of plasma total homocysteine levels: Impact of
population-wide folate fortification. Pharmacogenet Genomics 21: 426-431.
168.Institute
of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary
Reference Intakes and its Panel on Folate, Other B Vitamins and Choline (1998)
Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate,
vitamin B12, pantothenic acid, biotin and choline. The National Academies Press:
Washington DC.
169.Solis
C, Veenema K, Ivanov AA, Tran S, Li R, et al. (2008) Folate intake at RDA
levels is inadequate for Mexican Am men with the methylenetetrahydrofolate
reductase 677TT genotype. J Nutr 138: 67-72.
170.Stamm
RA, Houghton LA (2013) Nutrient intake values for folate during pregnancy and
lactation vary widely around the world. Nutrients 5: 3920-3947.
171.Australian
Government Department of Health Nutrient (2006) Reference Values.
172.Clinical
Guideline (2014) Vitamin and mineral supplementation in pregnancy. Policy
developed by: SA Maternal and Neonatal Clinical Network. Government of South
Australia. Available at: https://www.sahealth.sa.gov.au/wps/wcm/connect/f53d44004eee83bc8104a36a7ac0d6e4/Vitamin+mineral+supplementation_Clinical+Guideline_final_Dec14.pdf?MOD=AJPERES&CACHEID=f53d44004eee83bc8104a36a7ac0d6e4
173.Colson
NJ, Naug H, Nikbakht E, Zhang P, Mc Cormack J (2017) The impact of MTHFR 677 C/T
genotypes on folate status markers: A meta‑analysis of folic acid intervention
studies. Eur J Nutr 56: 247-260.
174.MRC
Vitamin Study Research Group (1991) Prevention of neural tube defects: Results of
the Medical Research Council. Lancet 338: 131-137.
175.Czeizel
AE, Dudás I (1992) Prevention of the first occurrence of neural-tube defects by
periconceptional vitamin supplementation. N Engl J Med 327: 1832-1835.
176.Berry
RJ, Li Z, Erickson JD, Li S, Moore CA, et al. (1999) Prevention of neural-tube
defects with folic acid in China. N Engl J Med 341: 1485-1490.
177.Moore,
KL, Persaud T (1998) Before we are born: Essentials of embryology and birth
defects. Philadelphia: WB Saunders Company.
178.Department
of Health (1992) Folic acid and the prevention of neural tube defects report
from an expert advisory panel. London: HMSO.
179.Brough
L, Rees GA, Crawford MA, Dorman EK (2009) Social and ethnic differences in
folic acid use during preconception and early pregnancy in the UK: Effect on
maternal folate status. J Hum Nutr Diet 22: 100-107.
180.Bestwick
JP, Huttly WJ, Morris JK, Wald NJ (2014) Prevention of neural tube defects: A cross-sectional
study of the uptake of folic acid supplementation in nearly half a million
women. PLoS One 9: e89354.
181.Hodgetts
VA, Morris RK, Francis A, Gardosi J, Ismail KM (2015) Effectiveness of folic
acid supplementation in pregnancy on reducing the risk of small‐for‐gestational
age neonates: A population study, systematic review and meta‐analysis. BJOG
122: 478-490.
182.National
Diet and Nutrition Survey (2019) Years 1 to 9 of the Rolling Programme
(2008/2009-2016/2017): Time trend and income analyses. Public Health England.
PHE Publications.
183.Wald
NJ, Morris JK, Blakemore C (2018) Public health failure in the prevention of
neural tube defects: Time to abandon the tolerable upper intake level of folate.
Public Health Rev 39: 2.